Passage Bio financials
$4.63−0.96%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating income | -$49.3M | -$70.4M | -$108.4M | -$138.4M | -$185.7M | -$112.9M |
| Net income | -$45.5M | -$64.8M | -$102.1M | -$136.1M | -$185.4M | -$112.2M |
| Net margin | — | — | — | — | — | — |
| Diluted EPS | $-14.35 | $-21.04 | $-37.20 | $-50.00 | $-69.60 | $-58.20 |
| EBITDA | -$42.4M | -$62.1M | -$99.3M | -$131.7M | -$176.2M | -$111.1M |
| Operating cash flow | -$31.5M | -$48.0M | -$78.3M | -$118.2M | -$126.9M | -$80.5M |
| Free cash flow | -$31.5M | -$48.0M | -$78.4M | -$120.5M | -$144.5M | -$81.7M |
| Diluted shares | 3.2M | 3.1M | 2.7M | 2.7M | 2.7M | 1.9M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $46.3M | $37.6M | $21.7M | $34.6M | $129.0M | $135.0M |
| Short-term investments | $0.00 | $39.2M | $92.6M | $155.0M | $186.8M | $169.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $62.3M | $102.4M | $150.5M | $243.5M | $355.1M | $328.0M |
| Total liabilities | $43.5M | $41.2M | $39.3M | $42.2M | $36.4M | $23.3M |
| Shareholders' equity | $18.8M | $61.3M | $111.3M | $201.4M | $318.7M | $304.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology